BRAF and colorectal carcinoma: Results from this prespecified, exploratory biomarker analysis of BEACON CRC support the use of Enco+Cetux±Bini, for the treatment of patients with BRAF-V600E-mutant mCRC and provide important insights into the biology of response and resistance to MAPK-pathway-targeted therapy.